ASCOT-BPLA signals changes to hypertension guidelines
| dc.contributor.author | Rayner, Brian | |
| dc.date.accessioned | 2016-07-25T07:19:21Z | |
| dc.date.available | 2016-07-25T07:19:21Z | |
| dc.date.issued | 2005 | |
| dc.date.updated | 2016-01-07T10:26:27Z | |
| dc.description.abstract | The Anglo-Scandanavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA) was a multi-centre, prospective, randomised, controlled trial in 19 257 patients with hypertension, aged 40-79 years, with at least three other cardiovascular (CVS) risk factors. Patients were assigned to either arnlodipine (5-10 mg), adding perindopril (4-8 mg) as required (arnlodipine-based regimen, n = 9 639), or atenolol (50-100 mg), adding bendroflumethiazide (1.25-2.5 mg) and potassium as required (atenolol-based regimen, n = 9 618). The primary end-point was non-fatal myocardial infarction (MI) and fatal coronary heart disease (CHD). Although there was a non-significant 10% reduction in the primary end-point in favour of the arnlodipine-based regimen, the study was prematurely stopped after a median follow up of 5.5 years by the Data and Safety Monitoring Committee, because of clinically important reductions in secondary end-points (Table I). | |
| dc.identifier.apacitation | Rayner, B. (2005). ASCOT-BPLA signals changes to hypertension guidelines. <i>Cardiovascular Journal of Africa</i>, http://hdl.handle.net/11427/20658 | en_ZA |
| dc.identifier.chicagocitation | Rayner, Brian "ASCOT-BPLA signals changes to hypertension guidelines." <i>Cardiovascular Journal of Africa</i> (2005) http://hdl.handle.net/11427/20658 | en_ZA |
| dc.identifier.citation | Rayner, B. (2005). ASCOT-BPLA signals changes to hypertension guidelines: editorial. Cardiovascular Journal of South Africa, 16(5), 244-245. | |
| dc.identifier.issn | 1995-1892 | |
| dc.identifier.ris | TY - Journal Article AU - Rayner, Brian AB - The Anglo-Scandanavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA) was a multi-centre, prospective, randomised, controlled trial in 19 257 patients with hypertension, aged 40-79 years, with at least three other cardiovascular (CVS) risk factors. Patients were assigned to either arnlodipine (5-10 mg), adding perindopril (4-8 mg) as required (arnlodipine-based regimen, n = 9 639), or atenolol (50-100 mg), adding bendroflumethiazide (1.25-2.5 mg) and potassium as required (atenolol-based regimen, n = 9 618). The primary end-point was non-fatal myocardial infarction (MI) and fatal coronary heart disease (CHD). Although there was a non-significant 10% reduction in the primary end-point in favour of the arnlodipine-based regimen, the study was prematurely stopped after a median follow up of 5.5 years by the Data and Safety Monitoring Committee, because of clinically important reductions in secondary end-points (Table I). DA - 2005 DB - OpenUCT DP - University of Cape Town J1 - Cardiovascular Journal of Africa LK - https://open.uct.ac.za PB - University of Cape Town PY - 2005 SM - 1995-1892 T1 - ASCOT-BPLA signals changes to hypertension guidelines TI - ASCOT-BPLA signals changes to hypertension guidelines UR - http://hdl.handle.net/11427/20658 ER - | en_ZA |
| dc.identifier.uri | http://hdl.handle.net/11427/20658 | |
| dc.identifier.vancouvercitation | Rayner B. ASCOT-BPLA signals changes to hypertension guidelines. Cardiovascular Journal of Africa. 2005; http://hdl.handle.net/11427/20658. | en_ZA |
| dc.language.iso | eng | |
| dc.publisher.department | Division of Nephrology and Hypertension | en_ZA |
| dc.publisher.faculty | Faculty of Health Sciences | en_ZA |
| dc.publisher.institution | University of Cape Town | |
| dc.source | Cardiovascular Journal of Africa | |
| dc.source.uri | http://www.cvja.co.za/information.php | |
| dc.title | ASCOT-BPLA signals changes to hypertension guidelines | |
| dc.type | Journal Article | en_ZA |
| uct.type.filetype | Text | |
| uct.type.filetype | Image | |
| uct.type.publication | Research | en_ZA |
| uct.type.resource | Article | en_ZA |